CD8+ T lymphocytes: Although the overall CD3+ TIL population was shown to provide survival benefits for EOC patients [5], among CD3+ cells, intraepithelial CD8+ TIL appear to be central players in tumor immune control [25,26,27]. The gene discussed is CD8A; the disease is neoplasm.